Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NRXP -MC $35 m - 2x Phase 3 results imminent expected during this month , a potential 10 bagger here with positive data readouts
upcoming milestones expected during Q2:
Release of top-line data from its trial of NRX-101 in Treatment Resistant Suicidal Bipolar Depression
Release of top-line data from Northwestern University's Department of Defense funded trial of the main component of NRX-101 in Chronic Pain
NDA filing for IV Ketamine for treatment of Suicidal Depression
NRXP -MC $35 m - 2x Phase 3 results imminent expected during this month , a potential 10 bagger here with positive data readouts
Upcoming milestones expected during Q2:
Release of top-line data from its trial of NRX-101 in Treatment Resistant Suicidal Bipolar Depression
Release of top-line data from Northwestern University's Department of Defense funded trial of the main component of NRX-101 in Chronic Pain
NDA filing for IV Ketamine for treatment of Suicidal Depression
NRXP up 16% - 2x Phase 3 readouts imminent expected during this month - market cap only $52 million
EYEN $0.59 -has 2x approved drugs and 2x Phase 3 Drugs including a potential blockbuster .. stock is super cheap at 28 million valuation a great reboundplay here
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities
https://finance.yahoo.com/news/eyenovia-announces-updated-strategy-corporate-110000476.html
EYEN $0.59 -has 2x approved drugs and 2x Phase 3 Drugs including a potential blockbuster .. stock is super cheap at 28 million valuation a great reboundplay here
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities
https://finance.yahoo.com/news/eyenovia-announces-updated-strategy-corporate-110000476.html
(NRXP) MC $50m -Phase 3 results imminent for their bipolar depression drug expected this month and another Phase 3 results from their chronic back pain trial also expected in the coming weeks . With positive results this low floater going to explode toward $20 currently trading at $5.20 .Check out their presentation below for more informations
Presentation
https://www.nrxpharma.com/wp-content/uploads/NRx-Corporate-Presentation.pdf
(NRXP) MC $50m -Phase 3 results imminent for their bipolar depression drug expected this month and another Phase 3 results from their chronic back pain trial also expected in the coming weeks . With positive results this low floater going to explode toward $20 currently trading at $5.20 .Check out their presentation below for more informations
Presentation
https://www.nrxpharma.com/wp-content/uploads/NRx-Corporate-Presentation.pdf
NRXP -MC $50m -Phase 3 results imminent for their bipolar depression drug expected this month and another Phase 3 results from their chronic back pain trial also expected in the coming weeks . With positive results this low floater going to explode toward $20 currently trading at $5.20 .Check out their presentation below for more informations
Presentation
https://www.nrxpharma.com/wp-content/uploads/NRx-Corporate-Presentation.pdf
CNTB $1.70 -3x blockbuster in Phase 3 while trading way under its cash balance
ASLN $0.68 - MC $11 m -Cash $30+ M - has Phase 3 asset and 2 Phase 2 programs ongoing with data readout expected in Q2 .. great reboundplay adter the drop from $2..
ASLN $0.68 - MC $11 m -Cash $30+ M - has Phase 3 asset and 2 Phase 2 programs ongoing with data readout expected in Q2 .. great reboundplay adter the drop from $2
ASLN $0.75 - MC $12 m - Cash $30+ m - has phase 3 asset and more in phase 2 ..terrible underprcied gem here
ASLN $0.75 - MC $12 m - Cash $30+ m has phase 3 asset and more in phase 2 ..terrible underprcied gem here
ASLN $0.69 hot reboundplay after the big drop yesterday ...has very low valuation of 11 million and an attractive phase 3 ready pipeline , could run back above $1
LPCN -MC $20 m -blockbuster phase 2 data readout coming this month and final results of depression drug coming in Q2 ,more informations in their presentation below . This could be the next 10 bagger
presentation
https://ir.lipocine.com/download/Corp+Deck_Lipocine+-+March+2024_Final.pdf
TCON running next bomb could be LPCN $3.30 - MC $18 million traind under its Cash of $25 million and to report final results for their depression drug in Q2 and Phase 2 data for their potential blockbuster targeting liver cirrhosis expected THIS month .both stock have 10 bagger potential
TCON $0.29 up 17% -- interim results from their cancer drug coming during this month - market cap still at laughable 13 milion
TCON $0.25 -interin data readout coming within days - market cap only $10 million
TCON $0.25 about to breakout -check this analysis out https://sih-st-charts.stocktwits-cdn.com/fit-in/500x0/filters:quality(75)/production/original_565125742.png
TCON $0.23 - cancer data readout this month - Market cap only $11 million this could be more than just a 10 bagger guys .check out the link below HC Wainwright has $6 price target for the stock
https://sih-st-charts.stocktwits-cdn.com/fit-in/500x0/filters:quality(75)/production/original_565125742.png
TCON $0.23 - data readout this month - Market cap only $11 million this could be more than just a 10 bagger guys .check out the link below HC Wainwright has $6 price target for the stock
https://sih-st-charts.stocktwits-cdn.com/fit-in/500x0/filters:quality(75)/production/original_565125742.png
TCON $0.24 --HC with $6 PT check out their analysis below
https://sih-st-charts.stocktwits-cdn.com/fit-in/500x0/filters:quality(75)/production/original_565125742.png
TCON $0.24 with buy rating check out link below
https://sih-st-charts.stocktwits-cdn.com/fit-in/500x0/filters:quality(75)/production/original_565125742.png
TCON $0.24 results from cancer drug imminent --market cap laughable 11 million
Upcoming milestones :
updated efficacy and safety results during this month
complete nvasarc enrollment expected in Q1
final results anticipated during Q3 . If data are positive BLA filing will follow in Q4 with potential FDA approval by mid next year
AMLX $3 drops 85% =good rebound play
TCON now at 0.23 and still super cheap at $10 million valuation for a company that could have an approved cancer drug by next year in everything goes well
TCON $0.19 next to explode - market cap only 7 million has cancer drug with expected efficacy results coming this month and potential NDA filing later this year
TCON 0.18 - MC $6 m- Cancer drug with final data readout in Q3 and potential FDA approval by next year .. more efficacy data readout expcted this month if positive this stock likely going through the roof .
https://finance.yahoo.com/news/tracon-pharmaceuticals-reports-fourth-quarter-210200434.html
Upcoming milestones:
Complete accrual of the ENVASARC pivotal trial this quarter and report updated response rate data shortly thereafter and before the end of the quarter.
Report final data from ENVASARC pivotal trial in the second half of 2024.
TCON 0.17 - MC $5 m- Cancer drug with final data readout in Q3 and potential FDA approval by next year .. more efficacy data readout expcted this month if positive this stock likely going through the roof .
https://finance.yahoo.com/news/tracon-pharmaceuticals-reports-fourth-quarter-210200434.html
Upcoming milestones:
Complete accrual of the ENVASARC pivotal trial this quarter and report updated response rate data shortly thereafter and before the end of the quarter.
Report final data from ENVASARC pivotal trial in the second half of 2024.
TCON 0.17 - MC $5 m- Cancer treatment with final data readout in Q3 and potential FDA approval by next year .. more efficacy data readout expcted this month if positive this stock likely going through the roof .
https://finance.yahoo.com/news/tracon-pharmaceuticals-reports-fourth-quarter-210200434.html
Upcoming milestones:
Complete accrual of the ENVASARC pivotal trial this quarter and report updated response rate data shortly thereafter and before the end of the quarter.
Report final data from ENVASARC pivotal trial in the second half of 2024.
ALZN $1.15 up 20% ---market cap only 8 million and mutliple phase 2 programs in Alzheimer , Major Depression , Bipolar and so forth , a potential 10 bagger here
ALZN $1 next to explode a massive underpriced biotech with multiple phase 2 programs ongoing targeting blockbuster markets
NRXP $0.60 exploding higher about to release 2x Phase 3 results in the coming week
ALZN $0.95 -MC $6 m has HUGE product pipeline targeting blockuster indication like Alzheimer ,Depression ,Bipolar and so forth with some Phase 2 data readout expected later this year . the founder of the company is a large buyer of the stock see link below .
insider activity
http://openinsider.com/search?q=alzn
pipeline
https://alzamend.com/pipeline/
2x Phase 3 readouts expected in early Q2 while valuation is still super low at $44 million
NRXP hit $0.50 could run to $1+ ahead of the two phase 3 readouts in early Q2
NRXP $0.48 - 2x Phase 3 results from Bipolar Depression and Chronic back pain trials expected within weeks - very low valuation of only $44 million ...this has multi bagger potential
NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-announces-133000763.html
Company presentation
https://www.nrxpharma.com/wp-content/uploads/NRx-Corporate-Presentation.pdf
NRXP $0.48 - 2x Phase 3 results within weeks - very low valuation of only $44 million ...this has multi bagger potential
NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-announces-133000763.html